[go: up one dir, main page]

  • Tesla will mark the beginning of the end for this bull market, warns Ralph Nader

    Tesla will mark the beginning of the end for this bull market, warns Ralph Nader

    Tesla shares — unsafe at any speed? Apparently so, according to the consumer advocate and former presidential candidate, who issued a stark warning this week, not only on the pricey stock, but on the market as a whole.

  • Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 15%

    Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 15%

    The stock analysts at Goldman Sachs have been busy. The bank – one of the world’s largest and most influential investment and financial services organizations, with alumni in government positions throughout the major Western nations – maintains a cadre of Wall Street experts, who keep close tabs on the constant shiftings of the stock markets. The result is a wealth of expert opinion, backed by data, on the current go-to investments.All of this is bread and butter for TipRanks, a platform that makes financial recommendations accountable, and expensive institutional datasets available, to all investors. We’ve pulled up three of Goldman’s recent tech sector stock picks, and run them through TipRanks' Stock Screener tool to confirm that Goldman is in the majority on Wall Street in recommending these equities.So, here are the results. Three tech stocks that usually fly under the radar – but Goldman sees them all with more than 15% upside potential in the coming year.GSX Techedu, Inc. (GSX)First on our list is an education-related tech stock from China. GSX is a software company, providing educational packages for after-school tutoring. The company is a leader in the K-12, large-class, after-school market in China, an important segment in a culture that puts a premium on education.A combination of factors worked to push GSX shares sharply upward in December – as much as 24%. While’s China’s overall economic growth has been slowing in recent years, and the trade tensions with the US have put pressures on most sectors of the Chinese economy, Chinese parents still put a premium on giving their kids the best possible education. That cultural imperative helped insulate GSX, and the company showed a tremendous 460% year-over-year revenue gain in Q3, posting 557 million yuan in sales – approximately $80 million in US currency. Total student enrollment rose by 240%, to 820,000.When news broke of the Phase 1 trade agreement between the US and Chinese governments last month, however, Chinese markets experienced a broad rally – and that included GSX. Investors were suddenly bullish after the trade agreement was announced and the signing was scheduled, and more willing to invest – and a company with GSX’s proven recent growth was sure to attract plenty of investor attention.Goldman’s Christine Cho reviewed GSX, and outlined the major advantages of the stock for investors. First, regarding the educational market generally in China, she wrote, “We expect online AST penetration will grow from 15% of the total AST market to 41% over the same period, as we believe online AST courses have a wider reach given their scalability, lack of physical constraints and better affordability…” And, looking at GSX specifically, Cho laid out her firm’s line: “We believe its competitive moat lies in its technology DNA and ROI mindset, scalable business model via well-managed star teachers, and best-in-class operating efficiency…”Cho initiated coverage of this stock for Goldman, giving it a Buy rating and setting an aggressive price target of $45. Her target indicates confidence in an upside potential of 28% for the next 12 months. (To watch Cho’s track record, click here)Overall, investors and analysts are bullish on this stock. The price run-up in December pushed the share price to $35.25, well above the consensus price target. However, Cho’s new coverage, with her higher target, indicate the potential available in GSX shares. (See GSX stock analysis at TipRanks)Avaya Holdings Corporation (AVYA)The next two stock on our list are related, operating in the same sector and, more importantly, having just entered a strategic partnership. First up is Avaya Holdings, a holding company whose main subsidiary, Avaya, Inc., provides software in the business communication and collaboration niche. Avaya’s products offer services to unify communications, contact centers, and real-time video systems.Business communications is an essential niche; no company can do without an efficient system for managing its analog, digital, and online communications. Avaya has ridden that need, and put up strong revenue numbers from filling it. In Q4 of fiscal 2019, reported in November, the company showed $723 million in quarterly revenues, and $2.89 billion in annual revenues. These numbers reflect GAAP figures, and the annual total shows a 1.4% year-over-year gain. The company’s cash on hand has shown steady increases in the past year, and stands at $752 million.During the quarter, Avaya announced a partnership with RingCentral (more below), through which Ring will become Avaya’s sole provider of UCaaS solutions. In addition, Ring committed to paying $500 million to Avaya in return for stock shares and licensing rights. The move brings Avaya’s services and migration capabilities into combination with Ring’s UCaaS platform, for both companies’ benefit.Goldman Sachs sees plenty of reason for optimism in Avaya’s current situation. Writing for the firm, 4-star analyst Rod Hall says, “We believe the economics of the announced RingCentral deal are likely to drive Avaya’s revenue and profitability above consensus expectations… In our central case, we estimate that ACO conversions could add ~$28m in revenue to Avaya in the first full year of its availability…”Hall puts a Buy rating on AVYA shares and his price target of $18 suggests an upside of 28% for stock. (To watch Hall’s track record, click here)Shares in AVYA are priced at $14, and the average target of $16.25 suggests room for 16% growth in the coming year. The Moderate Buy analyst consensus rating is based on 6 reviews, including 4 Buys and 2 Holds. (See Avaya stock analysis at TipRanks)RingCentral, Inc. (RNG)Third on our list is Avaya’s new partner, RingCentral. RNG brings cloud computing to the realm of business communications, with software packages combining two staples of the modern office: telephone and computer systems. RingCentral Office, the company’s flagship product, is sync-compatible with popular business applications like Salesforce, Outlook, Google Docs, and DropBox, plus it provides RNG’s unique features in call forwarding, multiple telephone extensions, video conferencing, and screen sharing.RingCentral’s strong product, solving real problems and improving business efficiencies, has brought the company equally strong profits. Revenues and earnings were both up in Q3 2019, the most recent reported. EPS, at 22 cents, was up 15% year-over-year, and beat the forecast by 15%. Revenues came in at $222 million, showing an impressive 34% year-over-year growth. Strong profits and earnings, in turn, powered RNG’s share appreciation – the stock gained 108% in 2019.Heather Bellini, 5-star analyst with Goldman, was impressed enough by RNG’s performance to upgrade the stock from Neutral to Buy, while setting a $230 price target. Her target suggests a about 15% upside to the stock.In her comments, Bellini noted RNG’s fast-paced growth, and recent AVYA partnership’s potential to drive further growth. She writes, “We see continued runway for outperformance driven by secular growth from UCaaS adoption, enterprise traction, and continued evolution in the companies go-to-market strategy, most notably RingCentral’s recently announced partnership with Avaya.” (To watch Bellini’s track record, click here)RNG holds a Strong Buy rating from the analyst consensus, with 14 Buy ratings and just a single Hold. Shares are priced high, at $197.75, reflecting the stock’s recent gains. The average price target is $201.36, implying a 2% upside for the stock – but as cited above, Goldman analyst sees a 15% upside ahead for RingCentral. (See RingCentral stock analysis at TipRanks)

  • Mark Cuban: Where the ‘frothy’ market goes from here depends on one thing

    Mark Cuban: Where the ‘frothy’ market goes from here depends on one thing

    “Where else are you going to put your money?” the Dallas Mavericks owner asked, adding that low interest rates are like universal basic income, but for rich people.

  • Retirement: What Happens If a Spouse Dies?

    Retirement: What Happens If a Spouse Dies?

    You don't automatically get your spouse's IRA, 401(k), and other accounts when he or she dies. Here's how to plan so the right survivors get the funds.

  • Surgical Robotics Leader Dives As Sales, Earnings Growth Decelerate
    Investor's Business Daily

    Surgical Robotics Leader Dives As Sales, Earnings Growth Decelerate

    Surgical robotics giant Intuitive Surgical reported decelerating sales and earnings growth Thursday, leading ISRG stock to slide in after-hours trading. Procedure growth remained strong.

  • Wells Fargo former CEO John Stumpf fined $17.5 million, banned for life from banking
    American City Business Journals

    Wells Fargo former CEO John Stumpf fined $17.5 million, banned for life from banking

    Wells Fargo former Chairman and CEO John Stumpf agreed to a lifetime ban from the banking industry over the bank's 2016 sales-practices scandal.

  • Chipmaker Intel Smashes Fourth-Quarter Targets, Guides Higher
    Investor's Business Daily

    Chipmaker Intel Smashes Fourth-Quarter Targets, Guides Higher

    Chipmaking giant Intel late Thursday smashed Wall Street's sales and earnings targets for the fourth quarter. The Intel earnings report sent INTC stock surging in extended trading.

  • Barrons.com

    10 Companies Microsoft Could Buy to Boost Its Growing Cloud Business

    Microsoft’s huge run to a $1 trillion-plus valuation has been driven by the remarkable growth in its Azure cloud business.

  • Intel enjoys big rebound in cloud, but the future is still hazy

    Intel enjoys big rebound in cloud, but the future is still hazy

    Intel Corp. wrapped up a rocky 2019 by reporting record sales thanks to a big jump in sales of chips for data centers and cloud computing, but that rebound may just be temporary.

  • TheStreet.com

    7 Low-Risk Investments With High Returns in 2020

    If you're worried about stocks right now, here are some investments that offer returns with less stress.

  • Young trader’s epic Beyond Meat stock misfire: ‘Biggest mistake of my life’

    Young trader’s epic Beyond Meat stock misfire: ‘Biggest mistake of my life’

    For many veteran traders, $12,000 is a rounding error, but for someone just getting his feet wet in the options pits, well, losing that much will leave a mark. That’s what happened this week to an anonymous trader.

  • MarketWatch

    Broadcom: Deals with Apple could be worth $15 billion

    Broadcom Inc. disclosed Thursday afternoon new deals with Apple Inc. worth $15 billion, and shares moved higher in extended trading. In a filing with the Securities and Exchange Commission, the chip maker said that it had signed two multiyear statement of work agreements with the iPhone manufacturer for components that will be included in Apple products beginning this month. The two deals are in addition to an agreement to supply RF chips that Broadcom disclosed last summer. Broadcom said that the two new deals as well as the rest of the previously disclosed contract would lead to, in aggregate, $15 billion in revenue for the company. Broadcom shares gained about 2% in the after-hours trading session Thursday, while Apple supplier Skyworks Solutions Inc.'s shares declined despite a strong earnings report released Thursday afternoon.

  • I’m 38 with $315,000 saved for retirement, but have $30,000 in debt. Should I lower my 401(k) contributions to get rid of that debt?

    I’m 38 with $315,000 saved for retirement, but have $30,000 in debt. Should I lower my 401(k) contributions to get rid of that debt?

    Your issue is a common one: The average personal debt load (that’s debt excluding mortgages) of people with debt is about $38,000, according to research from Northwestern Mutual. Why is paying down debt so beneficial to you?

  • Intel stock jumps as cloud pushes quarterly revenue higher than $20 billion for first time

    Intel stock jumps as cloud pushes quarterly revenue higher than $20 billion for first time

    Intel Corp. shares rallied in the extended session Thursday after the chip maker’s quarterly results and outlook topped Wall Street estimates with a big beat in data-center sales.

  • A Tale of 3 Healthcare Stocks – 2 to Buy, and 1 to Sell

    A Tale of 3 Healthcare Stocks – 2 to Buy, and 1 to Sell

    When investment bank Oppenheimer talks, investors listen -- or they should.One of the 10 top performing research firms tracked by TipRanks, 61% of Oppenheimer's stock picks have "worked" historically, producing positive returns for investors. In fact, on average, these picks have generated positive returns approaching 12%, and well ahead of the stock market's long term 10% average returns.And spread across a field of nearly 11,000 stock picks over more than a decade, that's no fluke.So when Oppenheimer announced on Wednesday that it's taken a good hard look at the healthcare industry, and come up with two stocks it's confident it can recommend buying -- and one it's pretty sure should be sold -- this is advice investors should give careful consideration.Let's find out what Oppenheimer has to say, beginning with:Regeneron Pharmaceuticals (REGN)Regeneron is one of a strange breed in biotech -- a company that actually makes money. 32 years in business, Tarrytown, NY-based Regeneron develops medicines to treat a wide array of illnesses, everything from age-related macular degeneration and diabetic retinopathy (Eylea) to atopic dermatitis (Dupixent) to atherosclerotic cardiovascular disease (Praluent) and locally advanced cutaneous squamous cell carcinoma (Libtayo).Oppenheimer analyst Hartaj Singh makes the case that Regeneron -- already doing $7.6 billion in annual sales and earning in excess of $2.1 billion annually -- is preparing to advance to the "next level of commercial and R&D growth" as competition to Eylea abates and the company intensifies its focus on growing Dupixent sales -- a $10 billion potential market.At the same time, Singh is impressed with Regeneron's "burgeoning internally generated pipeline" in 2020, which the analyst calls "best-in-class," as well as with management's "renewed focus on cost control" and planned $1 billion share buyback. Combined, these two moves promise to increase profits -- then divide them up among fewer shares outstanding, accelerating growth in earnings per share.As a result, Singh rates Regeneron stock "outperform" with a $450 price target, promising better than 25% upside from current prices. (To watch Singh's track record, click here)However, Wall Street isn’t completely sold on Regeneron. TipRanks analysis of 11 analysts shows a consensus Moderate Buy rating, with 4 analysts recommending Buy, while 7 recommending Hold. The average 12-month price target on the stock is $396.33, representing about 10% increase. (See Regeneron stock analysis on TipRanks)Novavax (NVAX)Oppenheimer's second stock pick takes us back to more familiar territory: biotech stocks that aren't earning money (at least not yet). Analyst Kevin DeGeeter's pick of vaccine specialist Novavax is clearly headlines-driven, and specifically, timed to align with recent news that the coronavirus outbreak that began in Chinese provincial capital Wuhan, has now arrived in America, with the first reported U.S. infection reported in Seattle Wednesday.As DeGeeter explains, the "outbreak of potent new strain of coronavirus infections" will remind investors "of the power of NVAX's flexible vaccine development infrastructure." And yet, it's not the primary reason DeGeeter likes Novavax in 2020. This is because DeGeeter expects it will take Novavax a good six to nine months to develop a vaccine effective against the new Chinese illness -- by which time 2020 will be basically over.Rather, this analyst views the "upcoming Phase III readout in March from NanoFlu recombinant hemagglutinin (HA) protein nanoparticle for protection against seasonal influenza as the primary value driver" for Novavax stock. Strong Phase II clinical trial results have DeGeeter thinking that Phase III results will be likewise positive, and perhaps enough so to convince the U.S. Food and Drug Administration to approve NanoFlu for sale as early as 2021. Once that happens, DeGeeter sees a strong chance that Novavax will sell itself to a high bidder.For this reason, DeGeeter is positing a rise in share price from $7.20 currently, to $13 a share by early 2021. Granted, an 80% return in 12 months' time may sound optimistic, but it could actually be conservative. (To watch DeGeeter's track record, click here)On Wall Street, the average target price among analysts tracking Novavax stock is $17.38 per share -- 34% more than what Oppenheimer is promising. (See Novavax stock analysis on TipRanks)Amarin Corp (AMRN)As much as Oppenheimer's analysts like Regeneron and Novavax, they are quite bearish on Amarin, a seller of prescription-only omega-3 fatty acid capsules for treating high triglyceride levels in patients. Oppenheimer comes to its "underperform" recommendation on Amarin by an interesting route.To start with, analyst Leland Gershell notes that AstroZeneca's discontinuation of a clinical trial for a product (Epanova) that would compete with Amarin's triglycerides drug (Vascepa) is a positive for Amarin stock. Although other competing treatments exist (Acasti Pharma's CaPre for example, and Matinas BioPharma's MAT9001), the removal of Epanova from the mix implies greater market share for Vascepa -- and an increased, $13 price target for Amarin stock.That being said, Gershell warns that "AMRN's opportunity to exit through acquisition [is] diminishing," which is to say the chances of the company finding a buyer willing to acquire Amarin at a premium valuation don't look as good as they once did. For this reason, despite raising its price target on the stock, Oppenheimer's still ends up thinking that Amarin, at a share price of nearly $21 (i.e. still 60% above what it thinks the stock is worth), remains overpriced and unlikely to outperform the market from here on out.In short, despite improved prospects for its marquee drug, the fact that the prospects for the company fetching a premium buyout prices are worse means Amarin merits a sell rating.All in all, Wall Street almost evenly split between the bulls and those choosing to play it safe. Based on 10 analysts tracked in the last 3 months, 5 rate Amarin stock a Buy, 4 say Hold, while 1 issues a Sell. Notably, the 12-month average price target stands at $29.88, marking a nearly 44% in return potential for the stock. (See Novavax stock analysis on TipRanks)

  • The latest coronavirus stock screamers: Inovio Pharmaceuticals, Co-Diagnostics

    The latest coronavirus stock screamers: Inovio Pharmaceuticals, Co-Diagnostics

    As the coronavirus out of China spreads and gets deadlier, shares of health care companies that announce plans to take part in finding a vaccine, or identifying patients with the new strain, have rallied sharply in very active trading.

  • Alibaba, Luckin Coffee, Other China Stocks Pressured As Coronavirus Crisis Deepens
    Investor's Business Daily

    Alibaba, Luckin Coffee, Other China Stocks Pressured As Coronavirus Crisis Deepens

    China stocks such as Alibaba and Luckin Coffee came under pressure as the coronavirus crisis deepened, with several Chinese cities under lockdown.

  • Analysts: These 3 “Strong Buy” Penny Stocks Could Gain Over 50%

    Analysts: These 3 “Strong Buy” Penny Stocks Could Gain Over 50%

    Penny stocks are controversial, to say the least. When it comes to these under $1 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds.However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in terms of the amount of shares. On top of this, other more expensive and well-known names aren’t as likely to produce the colossal gains that penny stocks are capable of.Given the nature of these investments, Wall Street analysts recommend doing some due diligence before pulling the trigger, noting that not all penny stocks are bound for greatness.With this in mind, we set out on own search for compelling investments that look like a steal. Using TipRanks’ Stock Screener tool, we filtered the results by current share price, analyst consensus and price target upside to track down 3 penny stocks that have amassed enough analyst support to earn a “Strong Buy” consensus rating. Adding to the good news, each pick boasts over 50% upside potential. Let’s dive in.Lineage Cell Therapeutics (LCTX)Like the name implies, this biotech uses its proprietary cell-based therapy platform to develop specialized, terminally-differentiated human cells. These cells can potentially replace or support cells that are dysfunctional or absent as a result of a degenerative disease or traumatic injury, or even help the body defend itself against cancer. On the heels of its recent data readout, one analyst argues that the $0.81 price tag is a steal.The company just released data from the Phase 1/2a study for OpRegen, its retinal pigment epithelium cell transplant for advanced dry age-related macular degeneration (dry AMD). According to the results, the therapy produced significant improvements in vision, with no unexpected complications or serious adverse events reported. Not to mention for some patients, structural improvements in the retina and decreases in drusen density have been maintained, and there is evidence of the continued presence of transplanted OpRegen cells three years after the therapy was administered.Based on this outcome, Dawson James analyst Jason Kolbert stated, “The data continues to demonstrate improvements in visual acuity, pointing to what may be a robust new therapy for Dry Age-Related Macular Degeneration.” On top of this, he believes the fact that the Orbit Subretinal Delivery System (Orbit SDS) and a new Thawand-Inject (TAI) formulation of OpRegen have already demonstrated signs of success “continues to support the use of retinal pigment epithelial (RPE) cells.”With the analyst estimating that macular degeneration is a multi-billion dollar market opportunity, he thinks OpRegen is the lead product and the performance driver for LCTX. In line with his optimistic take, Kolbert maintained a Buy rating as well as the $6 price target. This brings the potential twelve-month gain to a whopping 641%. (To watch Kolbert’s track record, click here)It turns out that the rest of the Street wholeheartedly agrees with the Dawson James analyst. With 4 Buys and no Holds or Sells, the message is clear: LCTX is a Strong Buy. The $4.25 average price target puts the upside potential below Kolbert’s forecast at 431%. (See Lineage Cell price targets and analyst ratings on TipRanks)Great Panther Mining (GPL)Intermediate gold and silver mining and exploration company Great Panther operates three mines including the Tucano Gold Mine in Amapá State, Brazil and two primary silver mines in Mexico: the Guanajuato Mine Complex and the Topia Mine as well as owns the Coricancha Mine in Peru. At only $0.60 per share, some members of the Street see an attractive entry point.Part of the excitement surrounding the company is related to its recent production beat. On January 13, GPL announced that fourth quarter 2019 consolidated production reached 146,853 gold equivalent ounces, blowing expectations out of the water. Management stated that this strong result was driven primarily by a better-than-expected quarter in Tucano, with production landing at 34,181 ounces. While Roth Capital’s Jake Sekelsky acknowledges that the company beat his conservative estimate at Tucano thanks to additional tonnage from the Urucum North and Urucum South pits, he sees the geotechnical review at the UCS pit as an inflection point for shares.Also encouraging is management’s decision to raise non-dilutive cash at the end of Q4 and early Q1 2020 via two separate transactions. “Given the company's increased cash balance, we believe the company possesses the necessary working capital to move forward with the technical review at Tucano aimed at bringing the UCS pit back into production in 2021,” Sekelsky explained. He adds that this approach also de-risks GPL.To this end, the analyst stays on the bulls’ side. Along with his bullish call, Sekelsky bumped up the price target from $0.80 to $1, implying shares could be in for a 67% gain in the next twelve months. (To watch Sekelsky’s track record, click here)What does Wall Street have to say? It has been relatively quiet when it comes to analyst activity. That being said, the two other analysts that published a review in the last three months were also bullish, making the consensus rating a unanimous Strong Buy. To top it all off, the $1.38 average price target suggests that 128% upside could be in the cards. (See Great Panther price targets and analyst ratings on TipRanks)Auryn Resources, Inc. (AUG) The last penny stock on our list is another player in the metal mining and exploration space. Auryn currently has seven projects including two flagships: the Committee Bay high-grade gold project in Nunavut and the Sombrero copper-gold project in southern Peru. With the price per share landing at $1.27, Heiko Ihle of H.C. Wainwright tells investors to get on board before it takes off.After the company broke the news that the intrusives related to mineralization at its Sombrero project in Peru are from the same metallogenic event that previously created many of the top deposits in the Andahuaylas-Yauri belt, Ihle likes what he’s seeing. “We believe that the Sombrero project could host a world-class deposit within its 130,000-hectare land package,” he commented.Additionally, the analyst sees the Curibaya site as particularly promising. The asset’s initial sampling program delivered solid results, including 7,990 grams per tonne (gpt) silver, 17.65 gpt gold and 6.97% copper. According to Ihle, this outcome demonstrates the magnitude of precious and base metal grades at Curibaya.“As Auryn’s surficial data at Curibaya continues to line up, the firm intends on further refining its drill targets through geophysical surveys to provide the necessary resolution for subsurface drilling. Auryn plans to apply for drill permitting at the end of 1Q20 with the ultimate goal of drilling the project in 4Q20,” the analyst noted.Given that 2020 could see some important discoveries for AUG, it makes sense, then, that the analyst takes a bullish approach, leaving both a Buy rating and the $2 price target as is. Should the target be met, shares could be in for a 57% twelve-month climb. (To watch Ihle’s track record, click here)All in all, the rest of the Street has been impressed by AUG. Out of 3 total analysts, 102% see the stock as a Buy, making the Street consensus a Strong Buy. At $2.49, the average price target suggests 96% upside potential, surpassing Ihle’s estimate. (See Auryn price targets and analyst ratings on TipRanks)

  • NerdWallet

    Who Should Consider a Roth Conversion Now?

    If you’ve saved a lot for retirement, or your parents have, you could be affected by recent changes in the rules about retirement distributions. The recently enacted Secure Act eliminated…

  • Financial Times

    Intel: feeling chipper 

    Intel has finally regained its position as the world’s biggest chipmaker after more than a year in the cold. The more companies opt to rent data storage from cloud services the better Intel’s data centre unit performs. The downside is that technology giants tend to expand data centre capacity in fits and starts.

  • Benzinga

    BofA Raises Apple's Price Target, Expects 'Another Leg Up' Following Q1 Earnings

    Apple Inc. (NASDAQ: AAPL ) is expected to report strong fiscal first-quarter results when it reports Jan. 28, but further upside from then on is uncertain, according to BofA Securities. The Analyst Wamsi ...

  • Mortgage rates fall to the lowest level in three months — but this is a double-edged sword for home buyers

    Mortgage rates fall to the lowest level in three months — but this is a double-edged sword for home buyers

    Persistently low mortgage rates have both a positive and a negative influence on the housing market.